Vitamin D in liver disease: Current evidence and potential directions

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1863, Issue 4, 2017, Pages 907-916

  Elangovan, Harendran ^a   Chahal, Sarinder ^a   Gunton, Jenny E ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

VITAMIN D; VITAMIN D RECEPTOR;

AUTOIMMUNE LIVER DISEASE; CHRONIC HEPATITIS C; GENETIC POLYMORPHISM; HUMAN; LIVER DISEASE; LIVER TRANSPLANTATION; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; REVIEW; VACCINATION; VITAMIN D DEFICIENCY; VITAMIN D METABOLISM; VITAMIN SUPPLEMENTATION; ANIMAL; CLINICAL TRIAL (TOPIC); METABOLISM; PATHOLOGY;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; LIVER DISEASES; VITAMIN D;

EID: 85010704988     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2017.01.001     Document Type: Review

References (118)

1. [1] Holick, M.F., Vitamin D: evolutionary, physiological and health perspectives. Curr. Drug Targets, 12, 2011.
2. [2] Prosser, D.E., Jones, G., Enzymes involved in the activation and inactivation of vitamin D. Trends Biochem. Sci. 29 (2004), 664–673.
3. [3] Cheng, J.B., Levine, M.A., Bell, N.H., Mangelsdorf, D.J., Russell, D.W., Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc. Natl. Acad. Sci. U. S. A. 101 (2004), 7711–7715.
4. [4] Holick, M.F., Chen, T.C., Vitamin D deficiency: a worldwide problem with health consequences. Am. J. Clin. Nutr. 87 (2008), 1080s–1086s.
5. [5] St-Arnaud, R., Targeted inactivation of vitamin D hydroxylases in mice. Bone 25 (1999), 127–129.
6. [6] Thacher, T.D., Clarke, B.L., Vitamin D insufficiency. Mayo Clin. Proc. 86 (2011), 50–60.
7. [7] Heaney, R.P., Functional indices of vitamin D status and ramifications of vitamin D deficiency. Am. J. Clin. Nutr. 80 (2004), 1706S–1709S.
8. [8] Chapuy, M.C., Preziosi, P., Maamer, M., Arnaud, S., Galan, P., Hercberg, S., Meunier, P.J., Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos. Int. 7 (1997), 439–443.
9. [9] Palacios, C., Gonzalez, L., Is vitamin D deficiency a major global public health problem?. J. Steroid Biochem. Mol. Biol. 144PA (2014), 138–145.
10. [10] Makishima, M., Lu, T.T., Xie, W., Whitfield, G.K., Domoto, H., Evans, R.M., Haussler, M.R., Mangelsdorf, D.J., Vitamin D receptor as an intestinal bile acid sensor. Science 296 (2002), 1313–1316.
11. [11] Lee, S.M., Goellner, J.J., O'Brien, C.A., Pike, J.W., A humanized mouse model of hereditary 1,25-dihydroxyvitamin D-resistant rickets without alopecia. Endocrinology 155 (2014), 4137–4148.
12. [12] Malloy, P.J., Feldman, B.J., Cell-autonomous regulation of brown fat identity gene UCP1 by unliganded vitamin D receptor. Mol. Endocrinol. 27 (2013), 1632–1642.
13. [13] Han, S., Li, T., Ellis, E., Strom, S., Chiang, J.Y.L., A novel bile acid-activated vitamin D receptor signaling in human hepatocytes. Mol. Endocrinol. 24 (2010), 1151–1164.
14. [14] Gascon-Barre, M., Demers, C., Mirshahi, A., Neron, S., Zalzal, S., Nanci, A., The normal liver harbors the vitamin D nuclear receptor in nonparenchymal and biliary epithelial cells. Hepatology 37 (2003), 1034–1042.
15. [15] N. Ding, Ruth T. Yu, N. Subramaniam, Mara H. Sherman, C. Wilson, R. Rao, M. Leblanc, S. Coulter, M. He, C. Scott, Sue L. Lau, Annette R. Atkins, Grant D. Barish, Jenny E. Gunton, C. Liddle, M. Downes, Ronald M. Evans, A vitamin D receptor/SMAD genomic circuit gates hepatic fibrotic response, Cell, 153 601–613.
16. [16] Firrincieli, D., Zúñiga, S., Rey, C., Wendum, D., Lasnier, E., Rainteau, D., Braescu, T., Falguières, T., Boissan, M., Cadoret, A., Housset, C., Chignard, N., Vitamin D nuclear receptor deficiency promotes cholestatic liver injury by disruption of biliary epithelial cell junctions in mice. Hepatology 58 (2013), 1401–1412.
17. [17] Bhalla, A.K., Wojno, W.C., Goldring, M.B., Human articular chondrocytes acquire 1,25-(OH)2 vitamin D-3 receptors in culture. Biochim. Biophys. Acta 931 (1987), 26–32.
18. [18] Wang, Y., Zhu, J., DeLuca, H.F., Where is the vitamin D receptor?. Arch. Biochem. Biophys. 523 (2012), 123–133.
19. [19] Girgis, C.M., Mokbel, N., Cha, K.M., Houweling, P.J., Abboud, M., Fraser, D.R., Mason, R.S., Clifton-Bligh, R.J., Gunton, J.E., The vitamin D receptor (VDR) is expressed in skeletal muscle of male mice and modulates 25-hydroxyvitamin D (25OHD) uptake in myofibers. Endocrinology 155 (2014), 3227–3237.
20. [20] Chen, S., Law, C.S., Grigsby, C.L., Olsen, K., Hong, T.T., Zhang, Y., Yeghiazarians, Y., Gardner, D.G., Cardiomyocyte-specific deletion of the vitamin D receptor gene results in cardiac hypertrophy. Circulation 124 (2011), 1838–1847.
21. [21] Li, Q., Gao, Y., Jia, Z., Mishra, L., Guo, K., Li, Z., Le, X., Wei, D., Huang, S., Xie, K., Dysregulated Krüppel-like factor 4 and vitamin D receptor signaling contribute to progression of hepatocellular carcinoma. Gastroenterology 143 (2012), 799–810, e792.
22. [22] Pourgholami, M.H., Akhter, J., Lu, Y., Morris, D.L., In vitro and in vivo inhibition of liver cancer cells by 1,25-dihydroxyvitamin D3. Cancer Lett. 151 (2000), 97–102.
23. [23] Barchetta, I., Carotti, S., Labbadia, G., Gentilucci, U.V., Muda, A.O., Angelico, F., Silecchia, G., Leonetti, F., Fraioli, A., Picardi, A., Morini, S., Cavallo, M.G., Liver vitamin D receptor, CYP2R1, and CYP27A1 expression: relationship with liver histology and vitamin D3 levels in patients with nonalcoholic steatohepatitis or hepatitis C virus. Hepatology 56 (2012), 2180–2187.
24. [24] Lavanchy, D., Evolving epidemiology of hepatitis C virus. Clin. Microbiol. Infect. 17 (2011), 107–115.
25. [25] Arteh, J., Narra, S., Nair, S., Prevalence of vitamin D deficiency in chronic liver disease. Dig. Dis. Sci. 55 (2010), 2624–2628.
26. [26] Lange, C.M., Bojunga, J., Ramos-Lopez, E., von Wagner, M., Hassler, A., Vermehren, J., Herrmann, E., Badenhoop, K., Zeuzem, S., Sarrazin, C., Vitamin D deficiency and a CYP27B1-1260 promoter polymorphism are associated with chronic hepatitis C and poor response to interferon-alfa based therapy. J. Hepatol. 54 (2011), 887–893.
27. [27] Yano, M., Ikeda, M., Abe, K.-i., Dansako, H., Ohkoshi, S., Aoyagi, Y., Kato, N., Comprehensive analysis of the effects of ordinary nutrients on hepatitis C virus RNA replication in cell culture. Antimicrob. Agents Chemother. 51 (2007), 2016–2027.
28. [28] Gutierrez, J.A., Jones, K.A., Flores, R., Singhania, A., Woelk, C.H., Schooley, R.T., Wyles, D.L., Vitamin D metabolites inhibit hepatitis C virus and modulate cellular Gene expression. J. Virol. Antivir. Res., 3, 2014, 10.4172/2324-8955.1000129.
29. [29] Gal-Tanamy, M., Bachmetov, L., Ravid, A., Koren, R., Erman, A., Tur-Kaspa, R., Zemel, R., Vitamin D: an innate antiviral agent suppressing hepatitis C virus in human hepatocytes. Hepatology 54 (2011), 1570–1579.
30. [30] Yuasa, K., Naganuma, A., Sato, K., Ikeda, M., Kato, N., Takagi, H., Mori, M., Zinc is a negative regulator of hepatitis C virus RNA replication. Liver Int. 26 (2006), 1111–1118.
31. [31] Kitson, M.T., Sarrazin, C., Toniutto, P., Eslick, G.D., Roberts, S.K., Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis. J. Hepatol. 61 (2014), 1247–1252.
32. [32] Garcia-Alvarez, M., Pineda-Tenor, D., Jimenez-Sousa, M.A., Fernandez-Rodriguez, A., Guzman-Fulgencio, M., Resino, S., Relationship of vitamin D status with advanced liver fibrosis and response to hepatitis C virus therapy: a meta-analysis. Hepatology 60 (2014), 1541–1550.
33. [33] Pineda-Tenor, D., Garcia-Alvarez, M., Jimenez-Sousa, M.A., Fernandez-Rodriguez, A., Resino, S., Reply: to PMID 24975775. Hepatology, 62, 2015, 1643.
34. [34] Belle, A., Gizard, E., Conroy, G., Lopez, A., Bouvier-Alias, M., Rouanet, S., Peyrin-Biroulet, L., Pawlotsky, J.-M., Bronowicki, J.-P., 25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients. United European Gastroenterol. J., 2016, 10.1177/2050640616640157.
35. [35] Loftfield, E., O'Brien, T.R., Pfeiffer, R.M., Howell, C.D., Horst, R., Prokunina-Olsson, L., Weinstein, S.J., Albanes, D., Morgan, T.R., Freedman, N.D., Vitamin D status and virologic response to HCV therapy in the HALT-C and VIRAHEP-C trials. PLoS One, 11, 2016, e0166036.
36. [36] Ross, A.C., Manson, J.E., Abrams, S.A., Aloia, J.F., Brannon, P.M., Clinton, S.K., Durazo-Arvizu, R.A., Gallagher, J.C., Gallo, R.L., Jones, G., Kovacs, C.S., Mayne, S.T., Rosen, C.J., Shapses, S.A., The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J. Clin. Endocrinol. Metab. 96 (2011), 53–58.
37. [37] Terrier, B., Lapidus, N., Pol, S., Serfaty, L., Ratziu, V., Asselah, T., Thibault, V., Souberbielle, J.-C., Carrat, F., Cacoub, P., Vitamin D in addition to peg-interferon-alpha/ribavirin in chronic hepatitis C virus infection: ANRS-HC25-VITAVIC study. World J. Gastroenterol. 21 (2015), 5647–5653.
38. [38] Baur, K., Mertens, J.C., Schmitt, J., Iwata, R., Stieger, B., Frei, P., Seifert, B., Bischoff Ferrari, H.A., von Eckardstein, A., Mullhaupt, B., Geier, A., The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. Antivir. Ther. 17 (2012), 541–547.
39. [39] Garcia-Martin, E., Agundez, J.A., Maestro, M.L., Suarez, A., Vidaurreta, M., Martinez, C., Fernandez-Perez, C., Ortega, L., Ladero, J.M., Influence of vitamin D-related gene polymorphisms (CYP27B and VDR) on the response to interferon/ribavirin therapy in chronic hepatitis C. PLoS One, 8, 2013, e74764.
40. [40] Hung, C.-H., Hu, T.-H., Lu, S.-N., Chen, C.-H., Wang, J.-H., Lee, C.-M., Association of vitamin D receptor gene polymorphisms with response to peginterferon plus ribavirin in Asian patients with chronic hepatitis C. J. Formos. Med. Assoc. 115 (2016), 278–283.
41. [41] Arai, T., Atsukawa, M., Tsubota, A., Kondo, C., Shimada, N., Abe, H., Itokawa, N., Nakagawa, A., Okubo, T., Aizawa, Y., Iwakiri, K., Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C. J. Med. Virol. 87 (2015), 1904–1912.
42. [42] Abu-Mouch, S., Fireman, Z., Jarchovsky, J., Zeina, A.-R., Assy, N., Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients. World J. Gastroenterol. 17 (2011), 5184–5190.
43. [43] Nimer, A., Mouch, A., Vitamin D improves viral response in hepatitis C genotype 2-3 naive patients. World J. Gastroenterol. 18 (2012), 800–805.
44. [44] Grasso, A., Malfatti, F., De Leo, P., Martines, H., Fabris, P., Toscanini, F., Anselmo, M., Menardo, G., Insulin resistance predicts rapid virological response in non-diabetic, non-cirrhotic genotype 1 HCV patients treated with peginterferon alpha-2b plus ribavirin. J. Hepatol. 51 (2009), 984–990.
45. [45] Yokoyama, S., Takahashi, S., Kawakami, Y., Hayes, C.N., Kohno, H., Kohno, H., Tsuji, K., Aisaka, Y., Kira, S., Yamashina, K., Nonaka, M., Moriya, T., Kitamoto, M., Aimitsu, S., Nakanishi, T., Kawakami, H., Chayama, K., Effect of vitamin D supplementation on pegylated interferon/ribavirin therapy for chronic hepatitis C genotype 1b: a randomized controlled trial. J. Viral Hepat. 21 (2014), 348–356.
46. [46] Ladero, J.M., Torrejon, M.J., Sanchez-Pobre, P., Suarez, A., Cuenca, F., de la Orden, V., Devesa, M.J., Rodrigo, M., Estrada, V., Lopez-Alonso, G., Agundez, J.A., Vitamin D deficiency and vitamin D therapy in chronic hepatitis C. Ann. Hepatol. 12 (2013), 199–204.
47. [47] Esmat, G., El Raziky, M., Elsharkawy, A., Sabry, D., Hassany, M., Ahmed, A., Assem, N., El Kassas, M., Doss, W., Impact of vitamin D supplementation on sustained virological response in chronic hepatitis C genotype 4 patients treated by pegylated interferon/ribavirin. J. Interf. Cytokine Res. 35 (2015), 49–54.
48. [48] Farnik, H., Bojunga, J., Berger, A., Allwinn, R., Waidmann, O., Kronenberger, B., Keppler, O.T., Zeuzem, S., Sarrazin, C., Lange, C.M., Low vitamin D serum concentration is associated with high levels of hepatitis B virus replication in chronically infected patients. Hepatology 58 (2013), 1270–1276.
49. [49] Hoan, N.X., Khuyen, N., Binh, M.T., Giang, D.P., Van Tong, H., Hoan, P.Q., Trung, N.T., Anh, D.T., Toan, N.L., Meyer, C.G., Kremsner, P.G., Velavan, T.P., Song, L.H., Association of vitamin D deficiency with hepatitis B virus-related liver diseases. BMC Infect. Dis., 16, 2016, 507.
50. [50] Zhao, X.Y., Li, J., Wang, J.H., Habib, S., Wei, W., Sun, S.J., Strobel, H.W., Jia, J.D., Vitamin D serum level is associated with Child-Pugh score and metabolic enzyme imbalances, but not viral load in chronic hepatitis B patients. Medicine (Baltimore), 95, 2016, e3926.
51. [51] Chan, H.L., Elkhashab, M., Trinh, H., Tak, W.Y., Ma, X., Chuang, W.L., Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. J. Hepatol., 63, 2015.
52. [52] Chan, H.L., Elkhashab, M., Trinh, H., Tak, W.Y., Ma, X., Chuang, W.L., Kim, Y.J., Martins, E.B., Lin, L., Dinh, P., Charuworn, P., Foster, G.R., Marcellin, P., Association of baseline vitamin D levels with clinical parameters and treatment outcomes in chronic hepatitis B. J. Hepatol. 63 (2015), 1086–1092.
53. [53] Boglione, L., Cusato, J., De Nicolò, A., Cariti, G., Di Perri, G., D'Avolio, A., Role of CYP27B1 + 2838 promoter polymorphism in the treatment of chronic hepatitis B HBeAg negative with PEG-interferon. J. Viral Hepat. 22 (2015), 318–327.
54. [54] Huang, Y.W., Liao, Y.T., Chen, W., Chen, C.L., Hu, J.T., Liu, C.J., Lai, M.Y., Chen, P.J., Chen, D.S., Yang, S.S., Kao, J.H., Vitamin D receptor gene polymorphisms and distinct clinical phenotypes of hepatitis B carriers in Taiwan. Genes Immun. 11 (2010), 87–93.
55. [55] Li, J.H., Li, H.Q., Li, Z., Liu, Y., Gao, J.R., Zeng, X.J., Gou, C.Y., Zhu, X.L., Guo, X.H., Pan, L., Li, H., Association of Taq I T/C and Fok I C/T polymorphisms of vitamin D receptor gene with outcome of hepatitis B virus infection. Zhonghua Yi Xue Za Zhi 86 (2006), 1952–1956.
56. [56] Bellamy, R., Ruwende, C., Corrah, T., McAdam, K.P.W.J., Thursz, M., Whittle, H.C., Hill, A.V.S., Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J. Infect. Dis. 179 (1999), 721–724.
57. [57] Liu, P.T., Stenger, S., Li, H., Wenzel, L., Tan, B.H., Krutzik, S.R., Ochoa, M.T., Schauber, J., Wu, K., Meinken, C., Kamen, D.L., Wagner, M., Bals, R., Steinmeyer, A., Zugel, U., Gallo, R.L., Eisenberg, D., Hewison, M., Hollis, B.W., Adams, J.S., Bloom, B.R., Modlin, R.L., Toll-like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 311 (2006), 1770–1773.
58. [58] Zitt, E., Sprenger-Mahr, H., Knoll, F., Neyer, U., Lhotta, K., Vitamin D deficiency is associated with poor response to active hepatitis B immunisation in patients with chronic kidney disease. Vaccine 30 (2012), 931–935.
59. [59] Jhorawat, R., Jain, S., Pal, A., Nijhawan, S., Beniwal, P., Agarwal, D., Malhotra, V., Effect of vitamin D level on the immunogenicity to hepatitis B vaccination in dialysis patients. Indian J. Gastroenterol. 35 (2016), 67–71.
60. [60] Targher, G., Bertolini, L., Scala, L., Cigolini, M., Zenari, L., Falezza, G., Arcaro, G., Associations between serum 25-hydroxyvitamin D 3 concentrations and liver histology in patients with non-alcoholic fatty liver disease. Nutr. Metab. Cardiovasc. Dis. 17 (2007), 517–524.
61. [61] Wang, X., Li, W., Zhang, Y., Yang, Y., Qin, G., Association between vitamin D and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: results from a meta-analysis. Int. J. Clin. Exp. Med. 8 (2015), 17221–17234.
62. [62] Eliades, M., Spyrou, E., Agrawal, N., Lazo, M., Brancati, F.L., Potter, J.J., Meta-analysis: vitamin D and non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther., 38, 2013.
63. [63] Chung, G.E., Kim, D., Kwak, M.-S., Yang, J.I., Yim, J.Y., Lim, S.H., Itani, M., The serum vitamin D level is inversely correlated with nonalcoholic fatty liver disease. Clin. Mol. Hepatol. 22 (2016), 146–151.
64. [64] Bril, F., Maximos, M., Portillo-Sanchez, P., Biernacki, D., Lomonaco, R., Subbarayan, S., Relationship of vitamin D with insulin resistance and disease severity in non-alcoholic steatohepatitis. J. Hepatol., 62, 2015.
65. [65] Anty, R., Hastier, A., Canivet, C.M., Patouraux, S., Schneck, A.-S., Ferrari-Panaia, P., Ben-Amor, I., Saint-Paul, M.C., Gugenheim, J., Gual, P., Iannelli, A., Tran, A., Severe vitamin D deficiency is not associated with liver damage in morbidly obese patients. Obes. Surg. 26 (2016), 2138–2143.
66. [66] Diez Rodriguez, R., Ballesteros Pomar, M.D., Calleja Fernandez, A., Calleja Antolin, S., Cano Rodriguez, I., Linares Torres, P., Jorquera Plaza, F., Olcoz Goni, J.L., Vitamin D levels and bone turnover markers are not related to non-alcoholic fatty liver disease in severely obese patients. Nutr. Hosp. 30 (2014), 1256–1262.
67. [67] Patel, Y.A., Henao, R., Moylan, C.A., Guy, C.D., Piercy, D.L., Diehl, A.M., Abdelmalek, M.F., Vitamin D is not associated with severity in NAFLD: results of a paired clinical and gene expression profile analysis. Am. J. Gastroenterol., 2016.
68. [68] Roth, C.L., Elfers, C.T., Figlewicz, D.P., Melhorn, S.J., Morton, G.J., Hoofnagle, A., Yeh, M.M., Nelson, J.E., Kowdley, K.V., Vitamin D deficiency in obese rats exacerbates nonalcoholic fatty liver disease and increases hepatic resistin and toll-like receptor activation. Hepatology 55 (2012), 1103–1111.
69. [69] Nakano, T., Cheng, Y.F., Lai, C.Y., Hsu, L.W., Chang, Y.C., Deng, J.Y., Huang, Y.Z., Honda, H., Chen, K.D., Wang, C.C., Chiu, K.W., Jawan, B., Eng, H.L., Goto, S., Chen, C.L., Impact of artificial sunlight therapy on the progress of non-alcoholic fatty liver disease in rats. J. Hepatol. 55 (2011), 415–425.
70. [70] Zeitz, U., Weber, K., Soegiarto, D.W., Wolf, E., Balling, R., Erben, R.G., Impaired insulin secretory capacity in mice lacking a functional vitamin D receptor. FASEB J. 17 (2003), 509–511.
71. [71] Maestro, B., Molero, S., Bajo, S., Davila, N., Calle, C., Transcriptional activation of the human insulin receptor gene by 1,25-dihydroxyvitamin D(3). Cell Biochem. Funct. 20 (2002), 227–232.
72. [72] Alkharfy, K.M., Al-Daghri, N.M., Yakout, S.M., Hussain, T., Mohammed, A.K., Krishnaswamy, S., Influence of vitamin D treatment on transcriptional regulation of insulin-sensitive genes. Metab. Syndr. Relat. Disord. 11 (2013), 283–288.
73. [73] Manna, P., Jain, S.K., Vitamin D up-regulates glucose transporter 4 (GLUT4) translocation and glucose utilization mediated by cystathionine-gamma-lyase (CSE) activation and H2S formation in 3T3L1 adipocytes. J. Biol. Chem. 287 (2012), 42324–42332.
74. [74] Yu, S., Bruce, D., Froicu, M., Weaver, V., Cantorna, M.T., Failure of T cell homing, reduced CD4/CD8alphaalpha intraepithelial lymphocytes, and inflammation in the gut of vitamin D receptor KO mice. Proc. Natl. Acad. Sci. U. S. A. 105 (2008), 20834–20839.
75. [75] Nelson, J.E., Roth, C.L., Wilson, L.A., Yates, K.P., Aouizerat, B., Morgan-Stevenson, V., Whalen, E., Hoofnagle, A., Mason, M., Gersuk, V., Yeh, M.M., Kowdley, K.V., Vitamin D deficiency is associated with increased risk of non-alcoholic steatohepatitis in adults with non-alcoholic fatty liver disease: possible role for MAPK and NF-kappaB?. Am. J. Gastroenterol. 111 (2016), 852–863.
76. [76] Kaser, S., Moschen, A., Cayon, A., Kaser, A., Crespo, J., Pons-Romero, F., Ebenbichler, C.F., Patsch, J.R., Tilg, H., Adiponectin and its receptors in non-alcoholic steatohepatitis. Gut 54 (2005), 117–121.
77. [77] Hui, J.M., Hodge, A., Farrell, G.C., Kench, J.G., Kriketos, A., George, J., Beyond insulin resistance in NASH: TNF-alpha or adiponectin?. Hepatology 40 (2004), 46–54.
78. [78] Xu, A., Wang, Y., Keshaw, H., Xu, L.Y., Lam, K.S.L., Cooper, G.J.S., The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Investig. 112 (2003), 91–100.
79. [79] Miele, L., Valenza, V., La Torre, G., Montalto, M., Cammarota, G., Ricci, R., Mascianà, R., Forgione, A., Gabrieli, M.L., Perotti, G., Vecchio, F.M., Rapaccini, G., Gasbarrini, G., Day, C.P., Grieco, A., Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology 49 (2009), 1877–1887.
80. [80] Donnelly, K.L., Smith, C.I., Schwarzenberg, S.J., Jessurun, J., Boldt, M.D., Parks, E.J., Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005), 1343–1351.
81. [81] Ning, C., Liu, L., Lv, G., Yang, Y., Zhang, Y., Yu, R., Wang, Y., Zhu, J., Lipid metabolism and inflammation modulated by Vitamin D in liver of diabetic rats. Lipids Health Dis. 14 (2015), 1–9.
82. [82] Barchetta, I., Del Ben, M., Angelico, F., Di Martino, M., Fraioli, A., La Torre, G., Saulle, R., Perri, L., Morini, S., Tiberti, C., Bertoccini, L., Cimini, F.A., Panimolle, F., Catalano, C., Baroni, M.G., Cavallo, M.G., No effects of oral vitamin D supplementation on non-alcoholic fatty liver disease in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial. BMC Med., 14, 2016, 92.
83. [83] Kitson, M.T., Pham, A., Gordon, A., Kemp, W., Roberts, S.K., High-dose vitamin D supplementation and liver histology in NASH. Gut, 65, 2016.
84. [84] Sharifi, N., Amani, R., Hajiani, E., Cheraghian, B., Does vitamin D improve liver enzymes, oxidative stress, and inflammatory biomarkers in adults with non-alcoholic fatty liver disease? A randomized clinical trial. Endocrine 47 (2014), 70–80.
85. [85] Fan, L., Tu, X., Zhu, Y., Zhou, L., Pfeiffer, T., Feltens, R., Stoecker, W., Zhong, R., Genetic association of vitamin D receptor polymorphisms with autoimmune hepatitis and primary biliary cirrhosis in the Chinese. J. Gastroenterol. Hepatol. 20 (2005), 249–255.
86. [86] Halmos, B., Szalay, F., Cserniczky, T., Nemesanszky, E., Lakatos, P., Barlage, S., Schmitz, G., Romics, L., Csaszar, A., Association of primary biliary cirrhosis with vitamin D receptor BsmI genotype polymorphism in a Hungarian population. Dig. Dis. Sci. 45 (2000), 1091–1095.
87. [87] Vogel, A., Strassburg, C.P., Manns, M.P., Genetic association of vitamin D receptor polymorphisms with primary biliary cirrhosis and autoimmune hepatitis. Hepatology 35 (2002), 126–131.
88. [88] Lakatos, L.P., Bajnok, E., Hegedus, D., Toth, T., Lakatos, P., Szalay, F., Vitamin D receptor, oestrogen receptor-alpha gene and interleukin-1 receptor antagonist gene polymorphisms in Hungarian patients with primary biliary cirrhosis. Eur. J. Gastroenterol. Hepatol. 14 (2002), 733–740.
89. [89] Tanaka, A., Nezu, S., Uegaki, S., Kikuchi, K., Shibuya, A., Miyakawa, H., Takahashi, S.-i., Bianchi, I., Zermiani, P., Podda, M., Ohira, H., Invernizzi, P., Takikawa, H., Vitamin D receptor polymorphisms are associated with increased susceptibility to primary biliary cirrhosis in Japanese and Italian populations. J. Hepatol. 50 (2009), 1202–1209.
90. [90] Kempi, ska-Podhorecka, A., Wunsch, E., Jarowicz, T., Raszeja-Wyszomirska, J., Loniewska, B., Kaczmarczyk, M., Milkiewicz, M., Gorzata, Milkiewicz, P., Vitamin D receptor polymorphisms predispose to primary biliary cirrhosis and severity of the disease in polish population. Gastroenterol. Res. Pract., 2012, 2012, 8.
91. [91] Guo, G.Y., Shi, Y.Q., Wang, L., Ren, X., Han, Z.Y., Guo, C.C., Cui, L.N., Wang, J.B., Zhu, J., Wang, N., Zhang, J., Cai, Y., Han, Y., Zhou, X.M., Fan, D.M., Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis. Aliment. Pharmacol. Ther. 42 (2015), 221–230.
92. [92] Agmon-Levin, N., Kopilov, R., Selmi, C., Nussinovitch, U., Sánchez-Castañón, M., López-Hoyos, M., Amital, H., Kivity, S., Gershwin, E.M., Shoenfeld, Y., Vitamin D in primary biliary cirrhosis, a plausible marker of advanced disease. Immunol. Res. 61 (2015), 141–146.
93. [93] Liaskou, E., Jeffery, L.E., Trivedi, P.J., Reynolds, G.M., Suresh, S., Bruns, T., Adams, D.H., Sansom, D.M., Hirschfield, G.M., Loss of CD28 expression by liver-infiltrating T cells contributes to pathogenesis of primary sclerosing cholangitis. Gastroenterology 147 (2014), 221–232, e227.
94. [94] Redaelli, C.A., Wagner, M., Tien, Y.H., Mazzucchelli, L., Stahel, P.F., Schilling, M.K., Dufour, J.F., 1 alpha,25-dihydroxycholecalciferol reduces rejection and improves survival in rat liver allografts. Hepatology 34 (2001), 926–934.
95. [95] Xing, T., Qiu, G., Zhong, L., Ling, L., Huang, L., Peng, Z., Calcitriol reduces the occurrence of acute cellular rejection of liver transplants: a prospective controlled study. Die Pharmazie - Int. J. Pharm. Sci. 68 (2013), 821–826.
96. [96] Falleti, E., Bitetto, D., Fabris, C., Cmet, S., Fornasiere, E., Cussigh, A., Fontanini, E., Avellini, C., Barbina, G., Ceriani, E., Pirisi, M., Toniutto, P., Association between vitamin D receptor genetic polymorphisms and acute cellular rejection in liver-transplanted patients. Transpl. Int. 25 (2012), 314–322.
97. [97] Andraos, C., Koorsen, G., Knight, J.C., Bornman, L., Vitamin D receptor gene methylation is associated with ethnicity, tuberculosis, and TaqI polymorphism. Hum. Immunol. 72 (2011), 262–268.
98. [98] Uitterlinden, A.G., Fang, Y., Van Meurs, J.B., Pols, H.A., Van Leeuwen, J.P., Genetics and biology of vitamin D receptor polymorphisms. Gene 338 (2004), 143–156.
99. [99] Abramovitch, S., Dahan-Bachar, L., Sharvit, E., Weisman, Y., Tov, A.B., Brazowski, E., Vitamin D inhibits proliferation and profibrotic marker expression in hepatic stellate cells and decreases thioacetamide-induced liver fibrosis in rats. Gut, 60, 2011.
100. [100] Hochrath, K., Stokes, C.S., Geisel, J., Pollheimer, M.J., Fickert, P., Dooley, S., Lammert, F., Vitamin D modulates biliary fibrosis in ABCB4-deficient mice. Hepatol. Int. 8 (2014), 443–452.
101. [101] Abramovitch, S., Sharvit, E., Weisman, Y., Bentov, A., Brazowski, E., Cohen, G., Volovelsky, O., Reif, S., Vitamin D inhibits development of liver fibrosis in animal model but cannot ameliorate established cirrhosis. Am. J. Physiol. Gastrointest. Liver Physiol., 2014.
102. [102] Pilz, S., Putz-Bankuti, C., Gaksch, M., Spindelboeck, W., Haselberger, M., Rainer, F., Posch, A., Kreuzer, P., Stojakovic, T., Stadlbauer, V., Obermayer-Pietsch, B., Stauber, R., Effects of vitamin D supplementation on serum 25-hydroxyvitamin D concentrations in cirrhotic patients: a randomized controlled trial. Nutrients, 8, 2016, 278.
103. [103] Ruiz-Gaspa, S., Guanabens, N., Enjuanes, A., Peris, P., Martinez-Ferrer, A., de Osaba, M.J., Gonzalez, B., Alvarez, L., Monegal, A., Combalia, A., Pares, A., Lithocholic acid downregulates vitamin D effects in human osteoblasts. Eur. J. Clin. Investig. 40 (2010), 25–34.
104. [104] Duran, A., Hernandez, E.D., Reina-Campos, M., Castilla, E.A., Subramaniam, S., Raghunandan, S., Roberts, L.R., Kisseleva, T., Karin, M., Diaz-Meco, M.T., Moscat, J., p62/SQSTM1 by binding to vitamin D receptor inhibits hepatic stellate cell activity, fibrosis, and liver cancer. Cancer Cell 30 (2016), 595–609.
105. [105] Chiang, K.C., Persons, K.S., Istfan, N.W., Holick, M.F., Chen, T.C., Fish oil enhances the antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 on liver cancer cells. Anticancer Res. 29 (2009), 3591–3596.
106. [106] Ghous, Z., Akhter, J., Pourgholami, M.H., Morris, D.L., Inhibition of hepatocellular cancer by EB1089: in vitro and in vive study. Anticancer Res. 28 (2008), 3757–3761.
107. [107] Akhter, J., Lu, Y., Finlay, I., Pourgholami, M.H., Morris, D.L., 1Alpha,25-dihydroxyvitamin D3 and its analogues, EB1089 and CB1093, profoundly inhibit the in vitro proliferation of the human hepatoblastoma cell line HepG2. ANZ J. Surg. 71 (2001), 414–417.
108. [108] Sahpazidou, D., Stravoravdi, P., Toliou, T., Geromichalos, G., Zafiriou, G., Natsis, K., Gigis, P., Significant experimental decrease of the hepatocellular carcinoma incidence in C3H/Sy mice after long-term administration of EB1089, a vitamin D analogue. Oncol. Res. 13 (2003), 261–268.
109. [109] Pivonello, C., Provvisiero, D.P., Negri, M., Di Gennaro, G., De Angelis, C., Galdiero, G., Simeoli, C., De Martino, M.C., Colao, A., Pivonello, R., Potential role of vitamin D in restoring sensitivity to mTOR inhibitors in hepatocellular carcinoma (HCC): 1,25(OH)vitamin D (VITD) reverts everolimus (EVE) resistance in a HCC cell line. Endocr. Abstr., 41, 2016.
110. [110] Mertz, J.A., Conery, A.R., Bryant, B.M., Sandy, P., Balasubramanian, S., Mele, D.A., Bergeron, L., Sims, R.J. 3rd, Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc. Natl. Acad. Sci. U. S. A. 108 (2011), 16669–16674.
111. [111] Chen, J., Katz, L.H., Muñoz, N.M., Gu, S., Shin, J.-h., Jogunoori, W.S., Lee, M.-H., Belkin, M.D., Kim, S.-B., White, J.C., Andricovich, J., Tzatsos, A., Li, S., Kim, S.S., Shetty, K., Mishra, B., Rashid, A., Lee, J.-S., Mishra, L., Vitamin D deficiency promotes liver tumor growth in transforming growth factor-β/Smad3-deficient mice through Wnt and toll-like receptor 7 pathway modulation. Sci. Rep., 6, 2016, 30217.
112. [112] ETHIER, C., KESTEKIAN, R., BEAULIEU, C., DUBE, C., HAVRANKOVA, J., GASCON-BARRE, M., Vitamin D depletion retards the normal regeneration process after partial hepatectomy in the rat. Endocrinology 126 (1990), 2947–2959.
113. [113] Sherman, M.H., Yu, R.T., Engle, D.D., Ding, N., Atkins, A.R., Tiriac, H., Collisson, E.A., Connor, F., Van Dyke, T., Kozlov, S., Martin, P., Tseng, T.W., Dawson, D.W., Donahue, T.R., Masamune, A., Shimosegawa, T., Apte, M.V., Wilson, J.S., Ng, B., Lau, S.L., Gunton, J.E., Wahl, G.M., Hunter, T., Drebin, J.A., O'Dwyer, P.J., Liddle, C., Tuveson, D.A., Downes, M., Evans, R.M., Vitamin D receptor-mediated stromal reprogramming suppresses pancreatitis and enhances pancreatic cancer therapy. Cell 159 (2014), 80–93.
114. [114] Morris, D.L., Jourdan, J.L., Finlay, I., Gruenberger, T., The, M.P., Pourgholami, M.H., Hepatic intra-arterial injection of 1,25-dihydroxyvitamin D3 in lipiodol: pilot study in patients with hepatocellular carcinoma. Int. J. Oncol. 21 (2002), 901–906.
115. [115] Dalhoff, K., Dancey, J., Astrup, L., Skovsgaard, T., Hamberg, K.J., Lofts, F.J., Rosmorduc, O., Erlinger, S., Bach Hansen, J., Steward, W.P., Skov, T., Burcharth, F., Evans, T.R.J., A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br. J. Cancer 89 (2003), 252–257.
116. [116] Umemura, A., He, F., Taniguchi, K., Nakagawa, H., Yamachika, S., Font-Burgada, J., Zhong, Z., Subramaniam, S., Raghunandan, S., Duran, A., Linares, J.F., Reina-Campos, M., Umemura, S., Valasek, M.A., Seki, E., Yamaguchi, K., Koike, K., Itoh, Y., Diaz-Meco, M.T., Moscat, J., Karin, M., p62, upregulated during preneoplasia, induces hepatocellular carcinogenesis by maintaining survival of stressed HCC-initiating cells. Cancer Cell 29 (2016), 935–948.
117. [117] Seif, A.A., Abdelwahed, D.M., Vitamin D ameliorates hepatic ischemic/reperfusion injury in rats. J. Physiol. Biochem. 70 (2014), 659–666.
118. [118] Kim, D., Kim, M., Chang, Y., Kim, J., Lee, J., Abstracts of the 37th ESPEN Congress, Lisbon, Portugal, 5–8 September 2015SUN-PP010: the vitamin D analogue paricalcitol attenuates hepatic ischemia/reperfusion injury by modulation of Tlr4-mediated signaling in rats. Clin. Nutr. 34 (2015), S26–S27.